You are here
Bill Burkoth is currently a Executive Director on the Pfizer's Venture Investments Team. Since joining Pfizer in early 2004, he has played an instrumental role in numerous new Pfizer venture investments. Bill currently serves as a director of DVS Sciences and Novocure, and as a board observer of Avid Radiopharmaceuticals, Evolution Benefits, HD Biosciences, M2S, and Nodality.
Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Bill began his career as an analyst at Bay City Capital, a leading life sciences venture capital firm. At Bay City, he evaluated numerous investment opportunities in biopharmaceuticals and assisted in the management of several portfolio companies.
Mr. Burkoth received a BS in chemistry from Whitman College and completed an executive MBA at Columbia Business School in 2011.